A marathon journey, united by one mission:

making healthcare for women both accurate and accessible.

Cervical cancer is the second leading cause of cancer deaths among women in Indonesia, with over 103 million women at risk. Yet, timely detection remains a challenge due to the limitations of current screening methods.

So, what if

every woman had access to early,accurate cervical cancer screening,regardless of where she lives?

Or, what if

we could eliminate cervical cancer by giving healthcare workers the tools to detect it early, anywhere?

Because we knew, if we could pull it off....

We would be able to bridge the gap in healthcare access.

Illustration

We could help healthcare workers diagnose faster and accurate.

Illustration

And this is what we've done so far

The Beginning of HerLens

November 2023, The Beginning of HerLens

We started by working with medical experts from Dr. Cipto Mangunkusumo National Central Public Hospital to test and refine the Visual Inspection with Acetic Acid (VIA) test, enhancing it with AI to support healthcare workers in making more accurate diagnoses.

From Vision to Validation

July 2024, From Vision to Validation

Building on our early progress, HerLens earned the STIC 2024 Business Grant. This recognition was a major milestone in our journey, validating the potential impact of our technology on improving women's health. This grant enables us to accelerate our MVP development and navigate the regulatory process more efficiently, putting us on track to test with real patients more quickly.

Building Momentum

September 2024, Building Momentum

Our ongoing partnership with the OB-GYN Department of Dr. Cipto Mangunkusumo National Hospital reached a new milestone as we passed the first regulatory process, paving the way for patient testing in their clinics. This achievement, coupled with our recognition as a finalist in the Hult Prize Global Accelerator 2024, brought HerLens into the global spotlight.

Taking the Next Step

March 2025, Taking the Next Step

With the first regulatory phase behind us, we began testing HerLens with real patients in clinics managed by the OB-GYN Department at Dr. Cipto Mangunkusumo National Hospital. Throughout this period, we continually refined our product based on feedback from the testing. Amidst all the busy work, we were unexpectedly honored to be named the winner of the National University of Singapore Health Hack 2025, adding a significant achievement to our journey.

This is just the beginning,

we believe healthcare for women should be accurate, accessible, and affordable.